Does <sup>18</sup>F-sodium fluoride PET/CT have a role in the assessment of response to <sup>223</sup>Ra therapy in men with prostatic bone metastases?
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42321542.
- Also identified by DOI 10.1007/s00259-026-08009-8.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The REASURE study investigated imaging biomarkers in men receiving <sup>223</sup>Ra treatment for prostate cancer bone metastases. We used REASURE data to compare and contrast the roles of [<sup>18</sup>F]NaF PET/CT measurements of maximum standardised uptake value (SUVmax) and bone metabolic flux (Ki) as markers of response. Thirty-four men with prostatic bone metastases received up to six cycles of <sup>223</sup>Ra (55 or 88 kBq/kg) at four-weekly intervals. Whole-body diffusion-weighted MRI and [<sup>18</sup>F]NaF PET/CT images were acquired at baseline and 4, 12, and 24 weeks later. Values of the apparent diffusion coefficient (ADC, a measure of tumour response), SUVmax, and a novel surrogate measurement of Ki using a PET/CT SUV measurement in the left ventricle were monitored in up to 5 bone metastases in each participant. Multilinear regression analysis (MLR) was performed to determine if changes in ADC were predicted by changes in SUVmax or Ki. Radium dose and baseline SUVmax were additional independent variables. ADC values increased throughout the study, while SUVmax and Ki decreased. MLR analysis showed that baseline SUVmax and <sup>223</sup>Ra dose predicted ADC response (P < 0.001 and P < 0.01, respectively). Changes in SUVmax and Ki at 4, 12, and 24 weeks failed to predict the changes in ADC, showing decoupling between MRI and PET/CT measurements as markers of response. Changes in Ki were a highly significant predictor of changes in SUVmax (P < 0.001), reflecting the strong correlation between these two measurements. Baseline SUVmax was the best predictor of ADC response, followed by <sup>223</sup>Ra dose. Changes in SUVmax and Ki failed to predict changes in ADC, suggesting that the changes in the PET/CT variables reflected the effect of <sup>223</sup>Ra uptake on osteoblasts rather than a tumoricidal effect. A decrease in SUVmax seen on post-therapy [<sup>18</sup>F]NaF PET/CT scans should not be interpreted as evidence of tumour regression. ISRCTN ISRCTN17805587. Registered 21/01/15.